Cargando…
Conversion from cilostazol to OPC‐13015 linked to mitigation of cognitive impairment
INTRODUCTION: Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol. METHODS: We prospectively enrolled patients with mild cognitive impairment to whom cilostazol was newly pre...
Autores principales: | Saito, Satoshi, Shinmyozu, Kaori, Kawakami, Daisuke, Yamauchi, Miho, Ikeda, Shuhei, Hattori, Yorito, Yamamoto, Rintaro, Hayakawa, Naoki, Ihara, Masafumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158162/ https://www.ncbi.nlm.nih.gov/pubmed/34095441 http://dx.doi.org/10.1002/trc2.12182 |
Ejemplares similares
-
Case Report: Postmortem brain and heart pathology unveiling the pathogenesis of coexisting acute ischemic stroke and electrocardiographic abnormality
por: Hattori, Yorito, et al.
Publicado: (2023) -
Cilostazol Add-On Therapy in Patients with Mild Dementia Receiving Donepezil: A Retrospective Study
por: Ihara, Masafumi, et al.
Publicado: (2014) -
Cilostazol, a Phosphodiesterase 3 Inhibitor, Moderately Attenuates Behaviors Depending on Sex in the Ts65Dn Mouse Model of Down Syndrome
por: Tsuji, Masahiro, et al.
Publicado: (2020) -
MIGRATION FROM OPC-DA TO OPC-UA
por: Farnham, B, et al.
Publicado: (2011) -
Impact of blood flow volume in determining the destination of intracardiac thrombi using computational fluid dynamics
por: Hattori, Yorito, et al.
Publicado: (2022)